Teriflunomide
Drug used in treatment of multiple sclerosis / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Teriflunomide?
Summarize this article for a 10 year old
Teriflunomide, sold under the brand name Aubagio, is the active metabolite of leflunomide.[4] Teriflunomide was investigated in the Phase III clinical trial TEMSO as a medication for multiple sclerosis (MS). The study was completed in July 2010.[5] 2-year results were positive.[6] However, the subsequent TENERE head-to-head comparison trial reported that "although permanent discontinuations [of therapy] were substantially less common among MS patients who received teriflunomide compared with interferon beta-1a, relapses were more common with teriflunomide."[7] The drug was approved for use in the United States in September 2012[8][9] and for use in the European Union in August 2013.[10]
Clinical data | |
---|---|
Trade names | Aubagio |
Other names | A77 1726 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a613010 |
License data |
|
Pregnancy category | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | >99.3% |
Elimination half-life | 2 weeks |
Excretion | Bile duct/fecal, kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.170.077 |
Chemical and physical data | |
Formula | C12H9F3N2O2 |
Molar mass | 270.211 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |